Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4 <sup>+</sup> T cells
Arnaud Pommier(Délégation Paris 5), Armelle Prévost‐Blondel(Délégation Paris 5), Cédric Auffray(Délégation Paris 5), Laëtitia Douguet(Institut Pasteur), Arnaud Delpoux(University of California San Diego), Masashi Kato(Nagoya University), Bruno Lucas(Centre National de la Recherche Scientifique), Renée Lengagne(Délégation Paris 5), Armelle Le Campion(Délégation Paris 5), Aurélie Durand(Centre National de la Recherche Scientifique), A. Audemard, Marie‐Françoise Avril(Délégation Paris 7), Bruno Martin(Centre National de la Recherche Scientifique)
Cited by 65
Related Papers
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
|Journal of Clinical Oncology|2011|463
Functional intestinal stem cells after Paneth cell ablation induced by the loss of transcription factor Math1 (Atoh1)
|Proceedings of the National Academy of Sciences|2012|309
Genome-wide association study identifies three new melanoma susceptibility loci
|Nature Genetics|2011|250
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
|Cell Research|2019|246